Debug, a Google initiative to reduce mosquito-borne diseases, announced Tuesday the expansion of its research and development (R&D) and mosquito production capabilities in Singapore.

This investment marks the establishment of Debug’s first international research and development (R&D) hub and its largest facility for adult mosquito production, Google said in a statement.

For over a decade, Debug has developed end-to-end technologies to help protect the 4 billion people worldwide at risk of dengue by integrating custom software, hardware automation, scientific innovation, and artificial intelligence (AI) in its mosquito suppression program.

At the core of this approach is Wolbachia, a naturally occurring bacterium that serves a precise, chemical-free method to prevent mosquitoes from spreading diseases.

To scale its impact, Debug is growing its team of software and hardware engineers alongside mosquito scientists in Singapore to accelerate the deployment of next-generation AI and robotics.

These advancements will enhance the scaled production of Wolbachia-carrying male mosquitoes, and additional innovations to offer more effective ways to manage mosquito-borne diseases in Singapore, Southeast Asia, and beyond.

This expansion builds on its years of production and releases in communities across countries like Singapore, Italy, Australia, and the United States, and comes as the initiative crosses a milestone of releasing more than 1 billion male mosquitoes globally since inception.

It is noted that Debug has been supporting the National Environment Agency (NEA) on Project Wolbachia since 2018 and opened its first end-to-end mosquito production facility in 2022.

By 2024, Debug released 6 million male Wolbachia mosquitoes per week to suppress the dengue vector population in the community and reduce the risks of dengue among residents.

Today, over 10 million are released weekly. Rigorous and extensive trials by NEA have shown that Project Wolbachia – Singapore has achieved 80 percent to 90 percent suppression of the Aedes aegypti mosquito population and more than 70 percent reduction in dengue incidents after 6 to 12 months of releases.

The expanded facility is designed to further this momentum by refining the core technologies that define Debug’s precision-rearing and release processes, including end-to-end robotics; optimized AI sex-sorting; automated mosquito releases.

By maximizing efficiency and male mosquito yields, Debug aims to make its technology more accessible, affordable, and effective.

While Debug’s current operations primarily focus on mosquito population suppression technology to reduce dengue cases in Singapore, the expanded facility introduces new R&D capabilities for mosquito population replacement for other markets.

This approach involves releasing mosquitoes that pass on Wolbachia to the next generation, eventually replacing the disease-carrying population with harmless ones as Wolbachia naturally blocks the transmission of dengue.

The expansion includes a new specialized larval rearing unit designed to develop innovations for replacement programs for deployment in other countries.

This additional offering allows Debug to deliver customized, effective cost-per-person protected targets tailored for other countries in Southeast Asia with larger populations.

While Aedes aegypti remains the priority, both the facility and the technology are built as a flexible, adaptive platform capable of rearing diverse mosquito species to tackle different vector-borne diseases.

“When we first launched Debug in Singapore, our goal was to advance mosquito production and releases through technology and bring Debug to more communities in Asia, where 70 percent of the global dengue burden occurs,

“Our success in Singapore gives us the confidence to expand. Choosing Singapore as our first international R&D hub underscores our confidence in the nation’s deep-tech ecosystem, talents, and its leadership in deploying the Wolbachia method,” said Linus Upson, Head of Debug.

According to him, this new chapter is about accelerating Asian-tailored solutions and scaling our experience to make Debug’s end-to-end technology accessible globally.

Ben King, Managing Director of Google Singapore, said this expansion of Google’s Debug in Singapore is a demonstration of how their technology, talent and leadership can come together to create impactful health outcomes for the community.

“This is a blueprint that reinforces Singapore’s standing as a global lighthouse for health tech,” he added

The expansion also aligns with Google’s broader commitment of expanding its Singapore R&D footprint to build deep, local research capabilities that serve the region, and develop new technologies across Google’s products and platforms, exporting innovation from Singapore to the world, said the statement.

Sea and Google deepen partnership to deliver AI-powered innovations for consumers globally